Literature DB >> 8475805

Unruptured intracranial arteriovenous malformations with hereditary haemorrhagic telangiectasia. Neurosurgical treatment or not?

J W ter Berg1, D W Dippel, J D Habbema, C J Westermann, C A Tulleken, J Willemse.   

Abstract

Clinical decision analysis is applied to treatment decisions for three patients with unruptured familial intracranial arteriovenous malformations (AVMs) in association with hereditary haemorrhagic telangiectasia (HHT). The grades of the AVMs--according to Spetzler--were 1-0-0 (two patients aged 12 and 14) and 2-0-1 (one patient aged 43). The AVM in one patient (graded 1-0-0) was operated on without sequelae. In the decision analysis, life expectancy is used as an outcome measure, with and without quality of life adjustment and discounting for time preference. It is concluded that neurosurgical treatment is the optimal strategy for all three patients. Because no conclusive data are available concerning the natural history and neurosurgical treatment of unruptured AVMs, we recommend the prospective application and testing of AVM grading systems. General treatment guidelines balancing the lifetime risk of haemorrhage, risk of incomplete extirpation and surgical mortality and morbidity are given. The analysis suggests that patients with low-graded AVMs which have not bled should be treated surgically, unless they are older than 60 years and have an increased risk of incomplete extirpation.

Entities:  

Mesh:

Year:  1993        PMID: 8475805     DOI: 10.1007/bf01405180

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  37 in total

1.  Pulmonary arteriovenous fistulas.

Authors:  D E Dines; R A Arms; P E Bernatz; M R Gomes
Journal:  Mayo Clin Proc       Date:  1974-07       Impact factor: 7.616

2.  Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients.

Authors:  H Sluiter-Eringa; N G Orie; H J Sluiter
Journal:  Am Rev Respir Dis       Date:  1969-08

3.  Familial association of intracranial aneurysms and multiple congenital anomalies.

Authors:  H W ter Berg; J B Bijlsma; J A Veiga Pires; J W Ludwig; C van der Heiden; C A Tulleken; J Willemse
Journal:  Arch Neurol       Date:  1986-01

4.  Anatomical grading of supratentorial arteriovenous malformations for determining operability.

Authors:  A J Luessenhop; T A Gennarelli
Journal:  Neurosurgery       Date:  1977 Jul-Aug       Impact factor: 4.654

5.  Decision analysis: a tool of the future: an application to unruptured arteriovenous malformations.

Authors:  W S Fisher
Journal:  Neurosurgery       Date:  1989-01       Impact factor: 4.654

6.  A proposed grading system for arteriovenous malformations.

Authors:  R F Spetzler; N A Martin
Journal:  J Neurosurg       Date:  1986-10       Impact factor: 5.115

7.  Natural history of arteriovenous malformations of the brain: a clinical study.

Authors:  D Fults; D L Kelly
Journal:  Neurosurgery       Date:  1984-11       Impact factor: 4.654

8.  Screening for unruptured familial intracranial aneurysms. A decision analysis.

Authors:  D W Dippel; J W ter Berg; J D Habbema
Journal:  Acta Neurol Scand       Date:  1992-10       Impact factor: 3.209

9.  Treatment of intact familial intracranial aneurysms: a decision-analytical approach.

Authors:  H W ter Berg; D W Dippel; J D Habbema; J B Bijlsma; J van Gijn; C A Tulleken; J Willemse
Journal:  Neurosurgery       Date:  1988-09       Impact factor: 4.654

10.  Treatment of unruptured cerebral arteriovenous malformations.

Authors:  M J Aminoff
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

View more
  2 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Recurrent epistaxes in hereditary haemorrhagic telangiectasia.

Authors:  S M Lim; R J Lane
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.